Clinical Trial Update: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for Lu-177 Ludotadipep in metastatic castration-resistant prostate cancer, with the study status listed as active but not recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Lu-177 Ludotadipep (Lutetium-177-ludotadipep)

Snippet

Sponsor: FutureChem | Conditions: Metastatic Castration-resistant Prostate Cancer, mCRPC | Phase 2 | Status: ACTIVE_NOT_RECRUITING